Ixekizumab and secukinumab for treating active psoriatic arthritis

Musculoskeletal

Blood and Immune System

Skin

31 August 2022

Published on 18 Jan 2021
Last Updated on 31 Aug 2022

Ixekizumab and secukinumab for treating active psoriatic arthritis Guidance is outdated and has been withdrawn on 31 August 2022. The Plain English Summary (PES) has been updated on 31 August 2022.

Interleukin inhibitors for treating chronic plaque psoriasis and active psoriatic arthritis PES (Updated 31 Aug 22) [PDF, 68 KB]

Ixekizumab and secukinumab for treating active psoriatic arthritis (Withdrawn 31 Aug 22) [PDF, 185 KB]